Boehringer returns to Sino Biopharma in $7.4B deal for preclinical TCEs, ADCs
7 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Boehringer returns to Sino Biopharma in $7.4B deal for preclinical TCEs, ADCs" is generating significant coverage in the Business category, with 7 articles from 7 distinct sources tracked by PULSE so far.
Outlets currently covering the story include FirstWord Pharma, Pharmaceutical Executive, Endpoints News and Bloomberg. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 11d ago.
Quick answers
Why is "Boehringer returns to Sino Biopharma in $7.4B deal for preclinical TCEs, ADCs" trending?
Because 7 independent news sources published 7 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (7)
- Boehringer in $7B cancer drug development deal with Sino Biopharm FirstWord Pharma · 13d ago
- Roundup: Boehringer Ingelheim Licenses Six Oncology Programs From Sino Biopharmaceutical, Nxera Licenses EP4 Agonist to AbbVie Pharmaceutical Executive · 13d ago
- Boehringer Ingelheim strikes $7B backloaded ADC, TCE cancer deal with China’s Sino Endpoints News · 13d ago
- Boehringer, Sino Enter Cancer Drug Deal Worth Over $7 Billion Bloomberg · 13d ago
- Boehringer announces new oncology partnership with SBP Group Boehringer Ingelheim · 13d ago
- Boehringer doubles down on China with $7B cancer deal Axios · 13d ago
- Boehringer returns to Sino Biopharma in $7.4B deal for preclinical TCEs, ADCs Fierce Biotech · 13d ago
Topics
Related trends
Xenon pauses phase 3 depression trials after psychosis events
Xenon shares fall as phase 3 depression trials are paused following psychosis events.
Updated: Electra says $350M IPO will help it become a commercial biotech
Immunology drugmaker Electra Therapeutics pursues an upsized $350 million initial public offering on Nasdaq under the ticker ETRA.
Takeda’s long-serving R&D chief Andy Plump to retire in wake of pipeline successes
Takeda Pharmaceutical's R&D chief Andy Plump is set to retire in June 2027 following a period of significant pipeline reorganization and regulatory success.
Unpacking Anthropic's 100-day sprint into biopharma: Nobel hires, M&A and major ambition
Anthropic is aggressively entering the biopharma sector through a 100-day sprint involving Nobel laureates, M&A activity, and new scientific AI tools.
China Plans AI Tech Export Curbs to Manage Security Risks
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Vir CEO sees ‘opportunity to do more deals’ after striking $1.9B Gilead pact for dual-masked TCEs
8 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.